Evidence map›Paper›PMID 18726678›Full record

ArticleJournal of clinical immunology2009

The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.

Marina Stolina, Brad Bolon, Scot Middleton, Denise Dwyer, Heather Brown, Diane Duryea, Li Zhu, Alison Rohner, James Pretorius, Paul Kostenuik and 2 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 75 citations in OpenAlex.

  1. Adjuvant-induced arthritis promotes vascular hyporesponsiveness to phenylephrine through a nitric oxide-related mechanism.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Article
  9. Preferential cyclooxygenase inhibition byJournal of traditional and complementary medicine · 2021
    Article
  10. Article
  11. Structural optimization of HPMA copolymer-based dexamethasone prodrug for improved treatment of inflammatory arthritis.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
  12. Article
  13. Article
  14. Anethole reduces inflammation and joint damage in rats with adjuvant-induced arthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Marina StolinaDepartment of Metabolic Disorders, Amgen, Thousand Oaks, CA 91320-1799, USA. mstolina@amgen.com
Brad Bolon
Scot Middleton
Denise Dwyer
Heather Brown
Diane Duryea
Li Zhu
Alison Rohner
James Pretorius
Paul Kostenuik
Ulrich Feige
Debra Zack
Amgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRats with adjuvant-induced arthritis (AIA) were necropsied on 14 occasions during preclinical, acute clinical and chronic clinical stages of AIA progression to characterize local (joint protein extracts) and systemic (serum) levels of mediators regulating inflammation and bone erosion in conjunction with lymphoid tissue-specific leukocyte kinetics.

resultsSystemic increases in alpha1 acid glycoprotein, tumor necrosis factor-alpha (TNFalpha), interleukin (IL)-17, transforming growth factor beta (TGFbeta), and chemokine (C-C motif) ligand 2 (CCL2) together with local IL-1alpha/beta and TGFbeta enrichment and local lymphoid hyperplasia preceded the onset of clinical disease and joint damage. Systemic upregulation of TNFalpha, IL-6, IL-17, TGFbeta, IL-18, CCL2, receptor activator of nuclear factor-kappabeta ligand (RANKL), and prostaglandin E(2) during acute and/or chronic AIA coincided with systemic leukocytosis and CD4+ T cell increase in blood and spleen. In contrast, progression of joint erosions during clinical AIA was associated with intra-articular increases in IL-1alpha/beta, IL-6, RANKL, IL-17, TGFbeta, CCL2, and KC/GRO and also a dramatic decline in osteoprotegerin.

conclusionThese data indicate that systemic and local events in inflammatory arthritis are discrete processes, driven by multiple cellular and humoral mediators with distinct kinetic profiles.

Indexed as

Adjuvants, ImmunologicAnimalsArthritis, ExperimentalBiomarkersCytokinesDisease ProgressionImmunoglobulinsLeukocytesMaleOsteoprotegerinRANK LigandRatsRats, Inbred LewAdjuvants, ImmunologicBiomarkersCytokinesImmunoglobulinsOsteoprotegerinRANK Ligand

Identifiers

PMID18726678
OpenAlexW2001323513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.